A Phase 3 interventional study of Ecnoglutide Injection and placebo with matching volume in Adolescents With Obesity and Adolescents With Overweight & Weight-related Comorbidities, sponsored by Hangzhou Sciwind Biosciences Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-09-23.
Sponsored by Hangzhou Sciwind Biosciences Co., Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Obesity by Hangzhou Sciwind Biosciences Co., Ltd. — 7 open to participants now, 8 under way, 4 of them phase 3. Obesity · Hangzhou Sciwind Biosciences Co., Ltd..
Among the 10 studies in Obesity by Hangzhou Sciwind Biosciences Co., Ltd., this one is the 3rd largest by planned enrollment, is one of 6 that started in 2026, is one of 5 in phase 3, and was the 8th registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →7 of the 10 studies in Obesity by Hangzhou Sciwind Biosciences Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:
Hangzhou Sciwind Biosciences Co., Ltd. · Sites in China
Ages 18–75
Hangzhou Sciwind Biosciences Co., Ltd. · Sites in China
Ages 18–75
Hangzhou Sciwind Biosciences Co., Ltd. · Sites in China
Ages 18–75
Hangzhou Sciwind Biosciences Co., Ltd. · Sites in China
Ages 18–65 · Healthy volunteers
Hangzhou Sciwind Biosciences Co., Ltd. · Sites in China
Ages 18–65
By country, each count listing its studies:
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 12 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 5
First in 2023; this study’s year is marked. 6 started in 2026.
This study's planned enrollment of 192 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 152 across the 10 interventional studies. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Hangzhou Sciwind Biosciences Co., Ltd. is the lead sponsor of 15 studies on the registry; 7 are open to participants now.
4 of the studies in Obesity by Hangzhou Sciwind Biosciences Co., Ltd. that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07243171Hangzhou Sciwind Biosciences Co., Ltd.A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity | 2027-01-05 |
| NCT07073417Hangzhou Sciwind Biosciences Co., Ltd.A Study to Compare XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity (SLIMMER-UP-SWITCH) | 2027-02-27 |
| NCT07936058Hangzhou Sciwind Biosciences Co., Ltd.A Phase I Study to Evaluate the Food Effect on Ecnoglutide Tablet | 2027-04-15 |
| NCT07929298Hangzhou Sciwind Biosciences Co., Ltd.A Study to Evaluate the Safety and Efficacy of Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity | 2027-09-03 |
Add all 4 to your calendar (.ics) → With an account.
Among the 10 studies in Obesity by Hangzhou Sciwind Biosciences Co., Ltd., from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of the study is to evaluate the safety and efficacy of Ecnoglutide injection in overweight or obese Chinese adolescents
In this study, eligible participants will be randomized into one of the three cohorts in a 3:1 ratio to receive either once-weekly subcutaneous Ecnoglutide injection or placebo, for up to 52 weeks
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
once weekly
Drug: Ecnoglutide Injection
once weekly
Drug: Ecnoglutide Injection
once weekly
Drug: Ecnoglutide Injection
once weekly
Drug: placebo with matching volume
Subcutaneous injection
Subcutaneous injection
Percent change in Body Mass Index (BMI)
Time frame: Baseline, week 40
Percentage of participants with ≥5% of BMI reduction
Time frame: Baseline, week 40 and week 52
Change in BMI
Include percent change and absolute change
Time frame: Baseline, week 52
Percentage of participants with ≥10% of BMI reduction
Time frame: Baseline, week 52
Percentage of participants with ≥15% of BMI reduction
Time frame: Baseline, week 52
Percentage of participants with ≥20% of BMI reduction
Time frame: Baseline, week 52
Change in body weight
Include percent change and absolute change
Time frame: Baseline, week 52
Change in Glycated Hemoglobin (HbA1c)
Time frame: Baseline, week 52
Change in Fasting Plasma Glucose (FPG)
Time frame: Baseline, week 52
Change in Fasting Insulin
Time frame: Baseline, week 52
Change in Homeostasis Model Assessment 2 - Insulin Resistance (HOMA2-IR)
Time frame: Baseline, week 52
Change in Homeostasis Model Assessment 2 - Beta Cell Function (HOMA2-β)
Time frame: Baseline, week 52
Change in lipid profile
Include triglycerides, LDL-C, HDL-C, total cholesterol
Time frame: Baseline, week 52
Change in liver enzymes
Include alanine aminotransferase, aspartate aminotransferase and gamma-glutamyl transferase
Time frame: Baseline, week 52
Adverse events
Incidence and severity
Time frame: From week1 to week 57
Trough concentration of ecnoglutide
Time frame: From baseline to week 57 (EOS)
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Jun 2028, 19 months later.
Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's planned 19 months is close to that.
Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ecnoglutide
Hangzhou Sciwind Biosciences Co., Ltd.